Available GM models
Genetically modified mouse models available for distribution
Ozgene is best known for providing genetically modified mouse models on a fee-for-service basis, where customers retain full ownership and rights to their lines. In select cases, Ozgene works with research organisations and foundations to make high-value models available to the wider research community. These models are bred and distributed directly by Ozgene.
NOW AVAILABLE
CureSHANK Shank3 conditional knockout
Shank3 conditional knockout mouse model
C57BL/6J | Exons 4–22 | Community-accessible
Access a genetically precise Shank3 conditional knockout (cKO) mouse model generated by Ozgene and available for global distribution under a collaboration with CureSHANK. This model supports research into Phelan-McDermid syndrome (PMS), SHANK3-related autism, and synaptic and neurodevelopmental biology, providing streamlined access for both academic and translational programs.
Shank3 mouse model at a glance:
- Community-accessible mouse model supporting PMS and SHANK3-related research
- Developed through a CureSHANK–Ozgene collaboration
- Integrated with InnoSer’s PMS preclinical testing platform
- Bred and distributed globally by Ozgene
Model design and genetic strategy
The Shank3 cKO model carries loxP sites flanking exons 4–22 of the Shank3 gene. When crossed with an appropriate Cre-driver line, Cre-mediated recombination excises these exons, producing a functional Shank3 knockout allele.
The exon-targeting strategy is based on previously published Ex4–22 deletion models (Wang et al., 2016; Drapeau et al., 2018), which demonstrated removal of all major murine Shank3 isoforms and exhibited behavioural, cognitive, and motor phenotypes associated with SHANK3 haploinsufficiency.
Genetic features:
- Model type: Conditional knockout (floxed Shank3 exons 4–22)
- Activation: Cre-mediated deletion
- Outcome: Functional Shank3 null allele
- Genetic background: C57BL/6J
- Generation technology: Ozgene’s patented goGermline™ technology
This design supports global or tissue-specific knockout studies, depending on the Cre line used, offering flexibility across diverse experimental programs.
Research applications
Based on prior published models and ongoing validation efforts, the Shank3 cKO mouse model supports a broad range of research applications, including:
- Phelan-McDermid syndrome (PMS)
- SHANK3-related autism spectrum disorder (ASD)
- SHANK3 haploinsufficiency and synaptic biology
- Neurodevelopmental and circuit-level dysfunction
- Preclinical evaluation of gene therapies
- Development of translational and behavioural biomarkers
The model is well suited for longitudinal studies, therapeutic testing, and platform-based preclinical programs.
Access, breeding, and distribution through Ozgene
Ozgene serves as the exclusive global distributor of the CureSHANK Shank3 conditional knockout mouse model, with active colonies maintained to support predictable and timely access.
Available options include:
- Study-ready experimental cohorts
- Breeding pairs or trios
- Custom background backcrossing
- Long-term colony management in the USA or Australia
Animals are supplied under standard use licenses permitting internal breeding and research. There are no reach-through IP claims, downstream royalties, or additional usage fees beyond the quoted animal cost. Onward distribution to third parties is not permitted.
Partnerships
Get started with the Shank3 cKO model
If you are planning studies in PMS, SHANK3-related ASD, or synaptic and neurodevelopmental biology, Ozgene can help you access the CureSHANK Shank3 conditional knockout mouse model and supporting services.
Get in touch
We provide tailored preclinical solutions to support your research, from genetically modified mouse models to breeding and phenotyping. Request a free quote today.
Fill out the form, and our team will respond within two business days. For stock strain enquiries, contact Ozgene ARC at arc@ozgene.com. For additional contact options, visit our contact page.
